Related references
Note: Only part of the references are listed.Efficacy of imatinib and chemotherapy in a pediatric patient with Philadelphia-like acute lymphoblastic leukemia with Ebf1-Pdgfrb fusion transcript
Francesca Fazio et al.
LEUKEMIA & LYMPHOMA (2020)
Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults
Robin Foa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Prognostic implications of additional genomic lesions in adult Philadelphia chromosome-positive acute lymphoblastic leukemia
Anna Lucia Fedullo et al.
HAEMATOLOGICA (2019)
Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements
Ilaria Tanasi et al.
BLOOD (2019)
The Validation of the BCR/ABL1-like Predictor across Laboratories Shows Reproducibility of Results
Sabina Chiaretti et al.
BLOOD (2019)
A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403
Wendy Stock et al.
BLOOD (2019)
BCR/ABL1-like acute lymphoblastic leukemia: How to diagnose and treat?
Sabina Chiaretti et al.
CANCER (2019)
Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group
Kathryn G. Roberts et al.
BLOOD (2018)
Rapid identification of BCR/ABL1-like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time-polymerase chain reaction: clinical, prognostic and therapeutic implications
Sabina Chiaretti et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults
Nitin Jain et al.
BLOOD (2017)
Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia
Sarah K. Tasian et al.
BLOOD (2017)
Adults with Philadelphia chromosome-like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis
Tobias Herold et al.
HAEMATOLOGICA (2017)
High incidence of Philadelphia chromosome-like acute lymphoblastic leukemia in older adults with B-ALL
S. K. Tasian et al.
LEUKEMIA (2017)
Adults with Philadelphia chromosome-like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis
Tobias Herold et al.
HAEMATOLOGICA (2017)
Characterisation of the genomic landscape of CRLF2-rearranged acute lymphoblastic leukemia
Lisa J. Russell et al.
GENES CHROMOSOMES & CANCER (2017)
High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment
Susan L. Heatley et al.
HAEMATOLOGICA (2017)
High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults
Kathryn G. Roberts et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment
Susan L. Heatley et al.
HAEMATOLOGICA (2017)
The biology of Philadelphia chromosome-like ALL
Kathryn G. Roberts
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2017)
Clinical significance of recurrent copy number aberrations in B-lineage acute lymphoblastic leukaemia without recurrent fusion genes across age cohorts
Monica Messina et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group
Shalini C. Reshmi et al.
BLOOD (2017)
CRLF2 overexpression identifies an unfavourable subgroup of adult B-cell precursor acute lymphoblastic leukemia lacking recurrent genetic abnormalities
Sabina Chiaretti et al.
LEUKEMIA RESEARCH (2016)
Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes
Monica Messina et al.
ONCOTARGET (2016)
Outcomes of Children With BCR-ABL1-Like Acute Lymphoblastic Leukemia Treated With Risk-Directed Therapy Based on the Levels of Minimal Residual Disease
Kathryn G. Roberts et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
K. G. Roberts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion
Etienne Lengline et al.
HAEMATOLOGICA (2013)
Tyrosine Kinase Inhibitor Therapy Induces Remission in a Patient With Refractory EBF1-PDGFRB-Positive Acute Lymphoblastic Leukemia
Brent W. Weston et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia
Shannon L. Maude et al.
BLOOD (2012)
Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia
Kathryn G. Roberts et al.
CANCER CELL (2012)
Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support
Paul A. Harris et al.
JOURNAL OF BIOMEDICAL INFORMATICS (2009)
A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study
Monique L. Den Boer et al.
LANCET ONCOLOGY (2009)
Deletion ofIKZF1and Prognosis in Acute Lymphoblastic Leukemia
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Share Paper
